Printer Friendly

Viral loads in clinical specimens and SARS manifestations.

A retrospective viral load study was performed on clinical specimens from 154 patients with laboratory-confirmed severe acute respiratory syndrome (SARS); the specimens were prospectively collected during patients' illness. Viral load in nasopharyngeal aspirates (n = 142) from day 10 to day 15 after onset of symptoms was associated with oxygen desaturatien, mechanical ventilation, diarrhea, hepatic dysfunction, and death. Serum viral load (n = 53) was associated with oxygen desaturation, mechanical ventilation, and death. Stool viral load (n = 94) was associated with diarrhea, and urine viral load (n = 111) was associated with abnormal urinalysis results. Viral replications at different sites are important in the pathogenesis of clinical and laboratory abnormalities of SARS.

**********

Severe acute respiratory syndrome (SARS) is an emerging infectious disease that affected 8,098 persons and caused 774 deaths from November l, 2002, to September 26, 2003 (1). A novel coronavirus (SARS-CoV) was consistently isolated from SARS patients in three different continents independently (2-4). Animal models using macaque monkeys, ferrets, and domestic cats were established (5-7); no extrapulmonary lesions could be identified in these animals, although virus isolation and reverse transcription-polymerase chain reaction (RT-PCR) results for viral RNA from pharyngeal secretions, tracheo-bronchial secretions, urine, rectal swabs or stool, kidney tissue or lung tissues were positive.

Recently, we reported the use of RT-PCR to detect SARS-CoV RNA from nasopharyngeal aspirates (NPA) and throat swab, urine, and stool specimens (8). We also developed quantitative RT-PCR (RT-qPCR) assays using the LightCycler System (Idaho Technology Inc., Idaho Falls, ID) to augment the sensitivity of detection (9). The serial viral load in NPA was also used to monitor clinical progress and response to antiviral therapy, and viral load in serum on admission was used as a marker of prognosis (10 12). Extrapulmonary manifestations, such as hematologic changes, diarrhea, and liver dysfunction are common in SARS patients but not in animal models (13-15). In this study, we assayed and analyzed viral load in clinical specimens taken from different anatomical sites from day 10 to 15 after the onset of symptoms to understand the role of SARS-CoV in the pathogenesis of clinical manifestations and laboratory test abnormalities in SARS patients.

Patients and Methods

We included in this quantitative virologic study 154 patients who fulfilled the modified World Health Organization (WHO) definition of SARS and whose treatment was managed in the United Christian Hospital and Caritas Medical Centre of Hong Kong Special Administration Region of China. All patients' infections were either serologically confirmed (fourfold rise of indirect immunofluorescent antibody titer in serum taken on admission and within 28 days of symptom onset) or RTPCR was positive for SARS-CoV RNA (confirmed from their clinical specimens for those who died or did not seroconvert before day 28). The case definition includes temperature of [greater than or equal to] 38[degrees]C, cough or shortness of breath, and new pulmonary infiltrates shown on chest x-ray or high-resolution computed tomographic scan in the absence of an alternative diagnosis to explain the clinical signs and symptoms.

The treatment protocol, clinical manifestations, and progression of disease in part of this cohort had been previously reported (10,11,16). In brief, patients were prospectively monitored for diarrhea, oxygen desaturation, mechanical ventilation; laboratory evidence of lymphopenia, renal impairment, liver dysfunction, or abnormal urinalysis during the first 15 days; and death. Diarrhea was defined as bowel movements [greater than or equal to] 3 times per day for 2 consecutive days. Oxygen desaturation was defined as <90% oxygen saturation measured by pulse oximetry while breathing room air. Some of these patients later required mechanical ventilation. Hepatic dysfunction was defined as a mean level of alanine aminotransferase (ALT), alkaline phosphatase (ALP), or both, greater than the upper limit of normal from day 10 to day 15 after onset of symptoms. Impaired renal function was defined as a serum creatinine level higher than the reference range on 2 consecutive days. Lymphopenia was defined as an absolute lymphocyte count <1,000/[micro]L on 2 consecutive days. Abnormal urinalysis results were defined as protein-uria (>30 mg/dL), microscopic hematuria (>10 erythrocytes/[micro]L), pyuria (>50 leukocytes/[micro]L) on a dipstick test, or casts in urine (Combur Test, Roche Diagnostics GmbH, Mannheim, Germany) examined with inverted microscope by an experienced technician.

To diagnose SARS-CoV infection, NPA and serum samples were taken on admission. Convalescent-phase serum samples were taken between days 7 and 28 after symptom onset. In all patients, RT-PCR for SARS-CoV RNA was performed on the NPA collected on admission. RT-qPCR was performed for patients who had NPA, serum, stool, and urine specimens collected on days 10 to 15 after the onset of symptoms. All virologic diagnostic laboratory tests, including viral culture, RT-PCR, RT-qPCR, and immunofluorescent antibody detection for immunoglobulin (Ig) G, were performed according to our previously published protocols (2,10). NPA was obtained by suction through both nostrils with a Pennine 6 mucus extractor (Pennine Healthcare, Derby, UK) and mucus specimen trap (MST-7000, Pennine Healthcare). The catheter was connected midway between the tip of the nose and the auditory meatus; it was rotated continuously and slowly retrieved with intermittent suction at a negative pressure of 100 mm Hg for 15 s. The procedure was repeated in the other nostril. Secretions stuck to the lumen of the catheter were transferred to the mucus trap by flushing with 1 mL of viral transport medium, which consists of Earle's Balanced Salt Solution (BioSource International, Camarillo, CA), 4.4% bicarbonate, 5% bovine serum albumin, vancomycin (100/[micro]g/mL), amikacin (30 [micro]g/mL), and nystatin (40 U/mL). A 10% stool suspension was made by swirling approximately 1 g of stool in 10 mL of viral transport medium. Midstream urine was collected in a sterile container. Serum from clotted blood was collected and stored at 4[degrees]C for antibody testing and at 20[degrees]C before RNA extraction. The other specimens were stored at 4[degrees]C before RNA extraction.

RNA from clinical samples was extracted by using the QIAamp virus RNA mini kit (Qiagen, Cologne, Germany) as instructed by the manufacturer. For all specimens, 140 [micro]L of the sample was used for RNA extraction, and extracted RNA was finally eluted in 30 [micro]L of RNase-free water and stored at -20[degrees]C. For the RT-qPCR assay, RNA and cDNA were generated as described (9). cDNA was amplified in a 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) by using TaqMan PCR Core Reagent kit (Applied Biosystems). In a typical reaction, 2 [micro]L of cDNA was amplified in a 25-[micro]L reaction containing 0.625 U AmpliTaq Gold polymerase (Applied Biosystems), 2.5 [micro]L of 10x TaqMan buffer A, 0.2 mmol/L of dNTPs, 5.5 mmol/L of Mg[Cl.sub.2], 2.5 U of AmpErase UNG, and 1x primers-probe mixture (Assays by Design, Applied Biosystems). The forward primer was 5'-CAGAACGCTGTAGCTTCAAAAATCT-3' (corresponding to nt 17,718-17,742 of the SARS-CoV genome), and the reverse primer was 5'-TCAGAACCCTGTGATGAATCAACAG-3' (corresponding to nt 17,761-17,785). The sequence of the reporter probe was 5'-(FAM)TCTGCGTAGGCAATCC(NFQ)-3' (FAM, 6-carboxyfluorescein; NFQ, nonfluorescent quencher; complementary to nt 17,745-17,760). Reactions were first incubated at 50[degrees]C for 2 min, followed by 95[degrees]C for 10 min. Reactions were then thermocycled for 40 cycles (95[degrees]C for 15 s, 60[degrees]C for 1 min). Plasmids containing the target sequences were used as standard controls. To monitor the integrity of RNA extraction for each sample, a housekeeping gene, [beta]-actin, was detected by real-time RT-PCR with two primers: [beta]-actin forward, 5'-CCCAAGGCCAACCGCGAGAAGAT-3' and reverse, 5'-GTCCCGGCCAGCCAGGTCCAG-3'. All samples were found to contain detectable [beta]-actin RNA.

All timed data were calculated from onset of symptoms. We compared the viral load in these specimens with the presence or absence of diarrhea, oxygen desaturation, mechanical ventilation, lymphopenia, hepatic dysfunction, abnormal urinalysis findings, and death rate by chi-square or Fisher exact test for categorical variables and by Mann-Whitney U test for continuous variables. A two-tailed p value < 0.05 was considered significant. Correlation between the number of anatomic sites with detectable viral load by RT-qPCR and death rate was calculated by linear regression. SPSS (version 11.0, SPSS Inc., Chicago, IL) was used for all analyses.

Results

Of the 154 SARS patients who satisfied the WHO definition for SARS, their age range was 20-80 years (mean 41.5 years). The male-to-female ratio was 0.60, and 31 (20.1%) were healthcare workers. One hundred and fifty patients (97.4%) were ethnic Chinese, and 4 (2.6%) were Filipino. The following clinical specimens taken from days 10 to 15 from individual patients were available: NPA (n = 142), serum (n = 53), stool (n = 94), and urine (n = 111). All patients had laboratory-confirmed SARS, either virologically by qualitative RT-PCR in 116 (75.3%) patients (from 30.5% of NPA, 68.2% of stool samples, and 26.6% of urine samples), by RT-qPCR in 126 (81.8%) patients (from 42.3% of NPA, 41.5% of serum samples, 87.2% of stool samples, and 28.8% of urine samples), or by seroconversion in indirect immunofluorescent antibody assay in 136 (88.3%) patients. Six patients who died before day 28 did not have serologic documentation, and 12 others had not seroconverted by day 28, but all had SARS confirmed by RT-PCR. Viral cultures were positive for SARS-CoV in 20 patients from NPA (n = 18), stool (n = 1), and urine (n = 1).

Besides fever and pulmonary infiltrates shown on x-ray, peripheral blood lymphopenia was the most common hematologic abnormality on admission and afterwards (Table 1). From admission to day 10, the peripheral lymphocyte count in all patients decreased. From days 10 to 19, the peripheral lymphocyte count continued to decrease in patients who ultimately died, whereas in those who survived, lymphocyte count gradually increased (Figure). Seroconversion to SARS-CoV antibodies also started at around day 10. Diarrhea (43.5%) was the most common extrapulmonary clinical manifestation from days 10 to 15, followed by hepatic dysfunction (39.0%). Abnormal urinalysis was found in 87 (56.4%) patients, with increased leukocyte esterase in 49.4%, pyuria in 23%, microscopic hematuria in 20.1%, and proteinuria in 3.8%. None of the patients had impaired renal function from admission to day 20. Oxygen desaturation developed in 73 patients (47.4%) at a mean of 10.2 (standard deviation [SD] = 5.1) days, and 34 patients (22.1%) died from SARS a mean of 32.4 (SD = 10.6) days after onset of symptoms. Only four patients were found to have abnormal mean ALP levels from admission to day 20. Therefore, only the mean ALT level from days 10 to 20 was analyzed for correlation with viral load. The mean ALT level between admission and day 10 was also analyzed. However, no significant association was found between the mean ALT level and the viral loads from different specimens.

[FIGURE OMITTED]

Both the positivity rate (87.2%) and the viral load by RT-qPCR (6.1 [log.sub.10] copies/mL) were highest for stool specimens, followed by NPA (42.3% and 2.4 [log.sub.10] copies/mL, respectively). Although virus was more frequently detected in serum (41.5%) than urine (28.8%), their mean viral loads for those specimens were 2.7 logl0 copies/mL and 4.4 [log.sub.10] copies/mL, respectively (Table 2). More patients with lymphopenia on admission had virus detectable by RT-qPCR in NPA (p = 0.04, odds ratio [OR] 2.2, 95% confidence interval [CI] 1.7-4.4, data not shown). Both the positivity rate and the viral load in NPA were significantly correlated with diarrhea, oxygen desaturation, mechanical ventilation, hepatic dysfunction, and death rate (all p < 0.01) (Tables 3 and 4). A high viral load in serum was also associated with oxygen desaturation, mechanical ventilation, hepatic dysfunction, and death (all p < 0.01) but not with diarrhea or abnormal urinalysis findings. Stool viral load was associated with diarrhea, hepatic dysfunction, abnormal urinalysis results, and death (all p < 0.01). A higher viral load in urine was significantly correlated with abnormal urinalysis and with diarrhea (both p < 0.01). These findings were confirmed by subgroup analysis of 40 patients with specimen samples taken from all four sites (NPA, serum, stool, and urine) (Tables 5 and 6). Again, a detectable viral load in NPA and serum was associated with oxygen desaturation (OR 5.3, 95% CI 1.4 21.1), mechanical ventilation (OR 1.6, 95% CI 1.1-2.4), and death (OR 1.8, 95% CI 1.2-2.7). The stool viral load was associated with diarrhea (OR 18, 95% CI 2.0-16.3), although a higher viral load in urine was no longer associated with abnormal urinalysis results.

In the subgroup analysis of 40 patients who had all types of specimen available for analysis, 34 had antibody seroconversion, and 6 died before day 28 without serologic documentation. Diagnosis of each was confirmed by qualitative RT-PCR. In this group, the number of anatomic sites with positive RT-qPCR strongly correlated with the risk for death (Pearson correlation = 0.517, p < 0.0005). No deaths were associated with negative RT-qPCR at all sites or just one positive site. Risk for death was 12.5% with positivity at two sites and 41.7% with positivity at three sites. The death rate increased to 66.7% if RT-qPCR was positive at all four sites.

Discussion

Viral load reflects the dynamic interaction between viral replication and clearance by body defense mechanisms. Examining viral load in SARS patients has been used to diagnose and monitor progress or response to antiviral therapy (10,11). We have shown that viral load in NPA peaked around day 10 (10), with a rapid decrease and concomitant normalization of lymphocyte count and rise in serum antibodies to SARS-CoV (Figure). Presence of virus and viral load in different body fluids may also bear on possible modes of transmission. Infectivity at day 10, reflected by a mean peak viral load of 5.8 [log.sub.l0] copies/mL and 7.0 [log.sub.10] copies/mL in positive specimens of NPA and stool, respectively, suggested that respiratory droplets and indirect contact with feces may be important mechanisms of transmission. Viral load has typically been measured in NPA and serum at admission as a diagnostic and prognostic tool (10,12,17). Viral load in body fluids other than NPA and serum has not been studied to elucidate transmission and pathogenesis of SARS.

The importance of SARS-CoV as a respiratory pathogen is supported by the strong association of viral load in NPA with oxygen desaturation, mechanical ventilation, and death. Unexpectedly, viral load in NPA was also associated with diarrhea and hepatic dysfunction. Anecdotal reports of the use of steroids to treat SARS tend to suggest these extrapulmonary manifestations could be part of an inflammatory "spillover" from virus-induced immune dysfunction or excessive cytokine activation in the lungs (18). However, our findings suggest that viral replication in extrapulmonary sites may be important, since viral load in stool is highly correlated with diarrhea, and electron microscopy of the ileum and colonic biopsy specimens from SARS patients showed numerous intracellular and extracellular virus particles (19). High viral load in urine is also associated with abnormal urinalysis findings. In this regard, SARS-CoV is currently known to grow only in fetal monkey kidney cells (i.e., fRhK4 or Vero E6) and the colonic carcinoma cell line (CACO-2). The correlation of viral load in stool with hepatic dysfunction is not completely unexpected, since high viral load in the stool is likely to be associated with significant portal venous viremia. In fact, viral load in stool is also associated with death.

Serum viral load correlates with oxygen desaturation, mechanical ventilation, and death. This finding is not surprising, since viremia has also been reported in adenovirus, respiratory syncytial virus (RSV), and rotavirus infections (20 22). However, viremia is reported to be short-lasting in mucosal infections. In one study, 5 out of 41 neonates with positive RSV antigen in nasal wash specimens were positive for RSV RNA in blood (21). High levels of adenovirus DNA in serum was also associated with death in children in whom adenovirus infection developed after allogeneic stem-cell transplantation. Six (86%) of 7 children who died of adenovirus infection, compared with 2 (7%) of 29 other patients, had high serum levels of adenoviral DNA (p < 0.0001) (20). The lack of association between viral load and lymphopenia at day 10 can be explained by the routine use of steroids, which induce apoptosis of lymphocytes. The apparently inferior performance of serum viral load as a prognostic indicator could be related to fewer available serum samples in this cohort. However, 38% of this group of 53 patients had oxygen desaturation; this proportion is not significantly different from the 142 patients (46%) who had submitted nasopharyngeal samples from day 10 to day 15.

Compared with other common viral respiratory diseases, the onset of peak viral load in the nasopharynx of SARS patients appears to be delayed. In a prospective study of viral shedding in nasopharyngeal secretions in experimental adult RSV infections, as measured by 50% tissue culture infective dose ([TCID.sub.50]) viral titer or RT-qPCR, RSV is detected from day 2 to day 12, with a plateau phase from day 3 to day 8, at a peak viral load of 5 [log.sub.10] copies/mL (23). In the case of experimental adult influenza, viral replication in NPA peaked [approximately equal to] 48 hours after the onset of symptoms and declined sharply thereafter, with an insignificant amount of viral shedding after day 8. Peak virus titers in symptomatic volunteers infected with influenza A H3N2 were [10.sub.2.5]-[10.sub.7.0] TCI[D.sub.50]/mL of nasopharyngeal wash. Viral load was positively correlated with symptoms of fever and malaise as well as the amount of viral shedding (24). However, the reported low incidence of viremia and the early peak nasopharyngeal viral load in these two conditions could be explained by inherent characteristics of viral replication, background IgG and IgA against cross-reactive homologous antigens from previous infections, or innate immunity of the host. In many of these experimental infections in which the profile of viral load in NPA was documented, volunteers were adults who had low-level background antibodies and concomitant cell-mediated immunity against influenza or RSV (23,24). Falsely negative serum viral load in influenza or RSV infection could be related to hemagglutinating properties of these two viruses, which may remain stuck on the erythrocyte in the clotted blood sample. In a novel emerging infectious disease such as SARS, most of the general population would not have background or partial immunity (2,25); viremia or a delayed peak viral load at day 10 in NPA is therefore not completely unexpected.

One limitation of the present study is its retrospective nature. Only specimens provided at approximately day 10 could be tested and analyzed. Changes of lymphocyte subsets were also not analyzed. Nonetheless, lymphocyte changes in SARS patients were well reported by two other groups who showed a consistent decrease in the peripheral blood level of dendritic cell subsets, natural killer cells, CD4+ and CD8+ T lymphocytes, and B lymphocytes (26,27).

SARS is predominantly a respiratory infection, which possibly spreads through the mucosal lumen or the bloodstream to extrapulmonary sites where viral replication leads to nonrespiratory manifestations. Concomitant immune dysregulation and associated inflammatory damage could accentuate disease progression and death. High viral load in NPA, with or without high viral load in serum, is a useful prognostic indicator of respiratory failure or death. The presence of viral RNA in multiple body sites also indicates poor prognosis. Early treatment with an effective antiviral agent before day 10 may decrease the peak viral load, ameliorate symptoms, and improve outcome; early treatment may also reduce viral shedding and thus the risk for transmission.
Table 1. The dominant clinical features and laboratory
abnormalities of 154 patients with SARS (a)

Clinical feature On admission (%) Days 10-15 (%)

Oxygen desaturation 2 (1.4) 73 (47.4)
Diarrhea 15 (10.6) 67 (43.5)
Lymphopenia 105 (68.1) 126 (81.8)
Hepatic dysfunction 34 (22.1) 60 (39.0)
Abnormal urinalysis NA 87 (56.4)
findings

(a) SARS, severe acute respiratory syndrome; NA, not applicable.

Table 2. SARS-CoV and viral load in different clinical specimens taken
during days 10 to 15 after the onset of symptoms (a)

 Mean viral load in [log.sub.10] copies/mL
Clinical specimens (SD), all specimens

NPA (n = 142) 2.4 (3.1)
Serum (n = 53) 1.1 (1.4)
Stool (n = 94) 6.1 (3.0)
Urine (n = 111) 1.3 (2.1)

 Mean viral load in [log.sub.10] copies/mL
Clinical specimens (SD), positive specimens only

NPA (n = 142) 5.8 (1.7)
Serum (n = 53) 2.7 (0.6)
Stool (n = 94) 7.0 (2.1)
Urine (n = 111) 4.4 (1.3)

Clinical specimens Positivity by RT-qPCR (%)

NPA (n = 142) 60/142 (42.3)
Serum (n = 53) 22/53 (41.5)
Stool (n = 94) 82/94 (87.2)
Urine (n = 111) 32/111 (28.8)

(a) SARS-CoV, severe acute respiratory syndrome-associated coronavirus;
SD, standard deviation; RT-qPCR, quantitative reverse
transcription-polymerase chain reaction; NPA, nasopharyngeal aspirates.

Table 3. Correlation of RT-qPCR of clinical specimens taken during days
10 to 15, and clinical manifestations in 154 patients with SARS (a)

 Diarrhea

 p value; OR
Specimen Y N (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 37 23 < 0.01; 2.5
 RT-qPCR (-) (n = 82) 32 50 (1.3-5.0)
 Median viral load ([log.sub.10] 3.2 0 0.02
 copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 12 10 0.4
 RT-qPCR (-) (n = 31) 13 18
 Median viral load 0 0 0.5
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 46 36 < 0.01; 14.1
 RT-qPCR (-) (n = 12) 1 11 (1.7-114.0)
 Median viral load 7.5 5 <0.01
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 23 9 < 0.01; 3.8
 RT-qPCR (-) (n = 79) 32 47 (1.5-9.2)
 Median viral load 0 0 < 0.01
 ([log.sub.10] copies/mL)

 [O.sub.2] desaturation

 p value; OR
Specimen Y N (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 37 23 < 0.01; 3.1
 RT-qPCR (-) (n = 82) 28 54 (1.6-6.2)
 Median viral load ([log.sub.10] 4.5 0 < 0.01
 copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 13 9 < 0.01; 5
 RT-qPCR (-) (n = 31) 7 24 (1.5-16.4)
 Median viral load 2.3 0 < 0.01
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 39 43 0.5
 RT-qPCR (-) (n = 12) 4 8
 Median viral load 7.2 5 0.1
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 15 17 0.8
 RT-qPCR (-) (n = 79) 34 45
 Median viral load 0 0 0.7
 ([log.sub.10] copies/mL)

 Mechanical ventilation

 p value; OR
Specimen Y N (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 22 38 < 0.01; 11.3
 RT-qPCR (-) (n = 82) 4 78 (3.6-35.1)
 Median viral load ([log.sub.10] 6.4 0 < 0.01
 copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 7 15 < 0.01; 1.5
 RT-qPCR (-) (n = 31) 0 31 (1.1-2.0)
 Median viral load 2.6 0 < 0.01
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 16 66 1
 RT-qPCR (-) (n = 12) 2 10
 Median viral load 8 7 0.05
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 7 25 0.4
 RT-qPCR (-) (n = 79) 12 67
 Median viral load 0 0 0.3
 ([log.sub.10] copies/mL)

 Death

 p value; OR
Specimen Y N (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 24 36 < 0.01; 54
 RT-qPCR (-) (n = 82) 1 81 (7.1-415.0)
 Median viral load ([log.sub.10] 6.5 0 < 0.01
 copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 8 14 < 0.01; 17.1
 RT-qPCR (-) (n = 31) 0 31 (2.0-151.0)
 Median viral load 2.6 0 < 0.01
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 17 65 0.5
 RT-qPCR (-) (n = 12) 1 11
 Median viral load 8.3 6.9 < 0.01
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 7 25 0.4
 RT-qPCR (-) (n = 79) 11 68
 Median viral load 0 0 0.4
 ([log.sub.10] copies/mL)

(a) RT-qPCR, quantitative reverse transcription polymerase chain
reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; OR,
odds ratio; CI, 95% confidence interval; NPA, nasopharyngeal aspirates

Table 4. Correlation of RT-gPCR clinical specimens taken during days 10
to 15 and laboratory values in 154 patients with SARS (a)

 Lymphopenia

Specimen Y N p value; OR (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 56 4 0.8
 RT-qPCR (-) (n = 82) 70 12
 Median viral load 0 0 0.3
 ([log.sub.10] copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 20 2 0.7
 RT-qPCR (-) (n = 31) 26 5
 Median viral load 0 0 0.4
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 75 7 0.2
 RT-qPCR (-) (n = 12) 9 3
 Median viral load 7.2 8.2 0.5
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 29 3 0.7
 RT-qPCR (-) (n = 79) 69 10
 Median viral load 0 0 0.3
 ([log.sub.10] copies/mL)

 Hepatic dysfunction

Specimen Y N p value; OR (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 40 20 < 0.01; 2.5 (1.2-5.2)
 RT-qPCR (-) (n = 82) 38 44
 Median viral load 2.7 0 0
 ([log.sub.10] copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 12 10 1
 RT-qPCR (-) (n = 31) 19 12
 Median viral load 0 0 0.9
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 46 36 0.1
 RT-qPCR (-) (n = 12) 4 8
 Median viral load 7.7 6.6 < 0.01
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 20 12 0.2
 RT-qPCR (-) (n = 79) 38 41
 Median viral load 0 0 0.2
 ([log.sub.10] copies/mL)

 Abnormal urinalysis results

Specimen Y N p value; OR (CI)

NPA (n = 142)
 RT-qPCR (+) (n = 60) 43 17 0.1
 RT-qPCR (-) (n = 82) 52 30
 Median viral load 0 0 0.1
 ([log.sub.10] copies/mL)
Serum (n = 53)
 RT-qPCR (+) (n = 22) 18 4 1
 RT-qPCR (-) (n = 31) 26 5
 Median viral load 0 0 0.5
 ([log.sub.10] copies/mL)
Stool (n = 94)
 RT-qPCR (+) (n = 82) 62 20 0.2
 RT-qPCR (-) (n = 12) 7 5
 Median viral load 7.6 3.1 0
 ([log.sub.10] copies/mL)
Urine (n = 111)
 RT-qPCR (+) (n = 32) 29 3 < 0.01; 7.2 (1.6-32.9)
 RT-qPCR (-) (n = 79) 50 29
 Median viral load 0 0 0
 ([log.sub.10] copies/mL)

(a) RT-qPCR, quantitative reverse transcription-polymerase chain
reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; OR,
odds ratio; CI, 95% confidence interval; NPA, nasopharyngeal
aspirates.

Table 5. Correlation of RT-qPCR clinical specimens taken during days
10 to 15, and clinical manifestations in 40 patients with SARS who had
specimens taken from all four anatomical sites (a)

 Diarrhea

 p value;
Specimen Y N OR (CI)

NPA (n = 40)
 RT-qPCR (+) (n = 18) 11 7 0.4

 RT-qPCR (-) (n = 22) 10 12
 Median viral load 2.9 0 0.4
([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 12 6 0.1

 RT-qPCR (-) (n = 22) 9 13
 Median viral load 2.3 0 0.3
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 20 10 < 0.01; 18
 (2.0-16.3)
 RT-qPCR (-) (n = 10) 1 9
 Median viral load 7.8 2.6 < 0.01
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 6 3 0.5
 RT-qPCR (-) (n = 31) 15 16
 Median viral load 0 0 0.4
 ([log.sub.10] copies/mL)

 [O.sub.2] desaturation

 p value;
Specimen Y N OR (CI)

NPA (n = 40)
 RT-qPCR (+) (n = 18) 11 7 0.02; 5.3
 (1.4-21.1)
 RT-qPCR (-) (n = 22) 5 17
 Median viral load 5.1 0 < 0.01
([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 11 7 0.02; 5.3
 (1.4-21.1)
 RT-qPCR (-) (n = 22) 5 17
 Median viral load 2.4 0 < 0.02
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 12 18 1

 RT-qPCR (-) (n = 10) 4 6
 Median viral load 7.3 7.2 0.5
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 3 6 0.7
 RT-qPCR (-) (n = 31) 13 18
 Median viral load 0 0 0.6
 ([log.sub.10] copies/mL)

 Mechanical ventilation

 p value;
Specimen Y N OR (CI)

NPA (n = 40)
 RT-qPCR (+) (n = 18) 7 11 < 0.01; 1.6
 (1.1-2.4)
 RT-qPCR (-) (n = 22) 0 22
 Median viral load 6.4 0 0
([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 7 11 < 0.01; 1.6
 (1.1-2.4)
 RT-qPCR (-) (n = 22) 0 22
 Median viral load 2.6 0 0
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 5 25 1

 RT-qPCR (-) (n = 10) 2 8
 Median viral load 8.2 7.2 0.5
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 1 8 1
 RT-qPCR (-) (n = 31) 6 25
 Median viral load 0 0 0.5
 ([log.sub.10] copies/mL)

 Death

 p value;
Specimen Y N OR (CI)

NPA (n = 40)
 RT-qPCR (+) (n = 18) 8 10 < 0.01; 1.8
 (1.2-2.7)
 RT-qPCR (-) (n = 22) 0 22
 Median viral load 6.4 0 < 0.01
([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 8 10 < 0.01; 1.8
 (1.2-2.7)
 RT-qPCR (-) (n = 22) 0 22
 Median viral load 2.6 0 < 0.01
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 7 23 0.7

 RT-qPCR (-) (n = 10) 1 9
 Median viral load 8.7 7 0
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 2 7 1
 RT-qPCR (-) (n = 31) 6 25
 Median viral load 0 0 1
 ([log.sub.10] copies/mL)

(a) RT-qPCR, quantitative reverse transcription-polymerase chain
reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; OR,
odds ratio; CI, 95% confidence interval; NPA, nasop haryngeal
aspirates.

Table 6. Correlation of RT-qPCR clinical specimens taken during days
10 to 15 and laboratory values in 40 patients with SARS who had
specimens taken from all four anatomic sites (a)

 Lymphopenia

Specimen Y N p value

NPA (n = 40)
 RT-qPCR (+) (n = 18) 15 3 0.6
 RT-qPCR (-) (n = 22) 20 2
 Median viral load 2.9 0 0.9
 ([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 16 2 1
 RT-qPCR (-) (n = 22) 19 3
 Median viral load 0 0 0.6
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 27 3 0.6
 RT-qPCR (-) (n = 10) 8 2
 Median viral load 7.9 7.2 0.8
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 8 1 1
 RT-qPCR (-) (n = 31) 27 4
 Median viral load 0 0 1
 ([log.sub.10] copies/mL)

 Hepatic dysfunction

Specimen Y N p value

NPA (n = 40)
 RT-qPCR (+) (n = 18) 10 8 0.8
 RT-qPCR (-) (n = 22) 11 11
 Median viral load 0 0 0.9
 ([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 10 8 0.8
 RT-qPCR (-) (n = 22) 11 11
 Median viral load 0 0 0.7
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 18 12 0.3
 RT-qPCR (-) (n = 10) 3 7
 Median viral load 7.8 4.7 0.04
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 7 2 0.1
 RT-qPCR (-) (n = 31) 14 17
 Median viral load 0 0 0.06
 ([log.sub.10] copies/mL)

 Abnormal urinalysis
 results

Specimen Y N p value

NPA (n = 40)
 RT-qPCR (+) (n = 18) 16 2 0.4
 RT-qPCR (-) (n = 22) 16 6
 Median viral load 0.8 0 0.5
 ([log.sub.10] copies/mL)
Serum (n = 40)
 RT-qPCR (+) (n = 18) 16 2 0.4
 RT-qPCR (-) (n = 22) 16 6
 Median viral load 1.1 0 0.3
 ([log.sub.10] copies/mL)
Stool (n = 40)
 RT-qPCR (+) (n = 30) 25 5 0.2
 RT-qPCR (-) (n = 10) 6 4
 Median viral load 7.8 2.6 0.1
 ([log.sub.10] copies/mL)
Urine (n = 40)
 RT-qPCR (+) (n = 9) 8 1 0.7
 RT-qPCR (-) (n = 31) 23 8
 Median viral load 0 0 0.4
 ([log.sub.10] copies/mL)

(a) RT-qPCR, quantitative reverse transcription-polymerase chain
reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; NPA,
nasopharyngeal aspirates.


Acknowledgments

We thank the staff members of the Department of Microbiology, Queen Mary Hospital; the Department of Medicine, United Christian Hospital; and Caritas Medical Centre.

This research was kindly supported by donations from the Infectious Diseases Fund (Mr. William Benter), the RFCID, and the Tung Wah Group of Hospitals.

References

(1.) World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 26 September 2003 [monograph on the internet]. 2003 Sep 26 [cited 2003 Sep 26]. Available from: http://www.who.int/csr/sars/country/table2003_09_23/en

(2.) Peiris JS, Lai ST. Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319-25.

(3.) Drosten C, Gunther S, Preiser W, van der Weft S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967-76.

(4.) Ksiazek TG, Erdman D. Goldsmith CS, Zaki SR, Peret T, Emery S. et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953-66.

(5.) Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Aetilogy: Koch's postulates fulfilled for SARS virus. Nature. 2003;423:240.

(6.) Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425:915.

(7.) Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263-70.

(8.) Yam WC, Chan KH, Pooh LL, Guan Y, Yuen KY, Seto WH, et al. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol. 2003;41:4521-4.

(9.) Poon LL, Chan KH, Wong OK, Yam WC, Yuen KY, Guan Y, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol. 2003;28:233-8.

(10.) Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Pooh LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72.

(11.) Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chart KS, et al. The role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-6.

(12.) Ng EK, Hui DS, Chan KC, Hung EC, Chiu RW, Lee N, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem. 2003;49:1976-80.

(13.) Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326:1358-62.

(14.) Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977-85.

(15.) Wong WM, Ho JC, Hung IF, Ng W, Lam YM, Tam WO, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SAILS. JAMA. 2003;290:2663-5.

(16.) Cheng VC, Hung IF, Tang BS, Chu CM, Wong MM, Chan KH, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with SARS. Clin Infect dis. 2004;38:467-75.

(17.) Grant PR, Garson JA, Tedder RS, Chan PK, Tam JS, Sting JJ. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med. 2003;349:2468-9.

(18.) Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773-8.

(19.) Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125:1011-7.

(20.) Schilham MW, Claas EC, van Zaane W, Heemskerk B, Vossen JM, Lankester AC. et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis. 2002;35:526-32.

(21.) Rohwedder A, Keminer O, Forster I, Schneider K, Schneider E, Werchau H. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. J Med Virol. 1998;54:320-7.

(22.) Blutt SE, Kirkwood CD, Parreno V, Warfield KL, Clarlet M, Estes MK, et al. Rotavirus antigenaemia and viraemia: a common event? Lancet. 2003;362:1445-9.

(23.) Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol. 2003;41:4160-5.

(24.) Boivin G, Coulombe Z, Wat C. Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir. J Infect Dis. 2003;188:578-80.

(25.) Woo PC, Lau SK, Tsoi HW, Chan KH, Wong BH, Che XY, et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet. 2004;363:841-5.

(26.) Cui W, Fan Y. Wu W, Zhang F, Wang JY, Ni AP. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003:37:857-9.

(27.) Li T, Qiu Z, Zhang L. Han Y, He W, Liu Z, et al. Significant changes of peripheral F lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189:648-51.

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

Dr. Hung is a fellow of infectious disease at Queen Mary Hospital. His research interests include infections in immuno-compromised persons and emerging infectious diseases.

I.F.N. Hung, * V.C.C. Cheng, * A.K.L. Wu, ([dagger]) B.S.F. Tang, * K.H. Chan, * C.M. Chu, ([double dagger]) M.M.L Wong, ([section]) W.T. Hui, * L.L.M. Poon, * D.M.W. Tse, ([section]) K.S. Chan, ([double dagger]) P.C.Y. Woo, * S.K.P. Lau, * J.S.M. Peiris, * and K.Y. Yuen *

* Queen Mary Hospital at the University of Hong Kong, Hong Kong Special Administrative Region (SAR), People's Republic of China; ([dagger]) Prince of Wales Hospital, Hong Kong SAR, People's Republic of China; ([double dagger]) United Christian Hospital, Hong Kong SAR, People's Republic of China; and ([section]) Caritas Medical Centre, Hong Kong SAR, People's Republic of China

Address for correspondence: K.Y. Yuen, Division of Infectious Disease, Center of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China; fax: 852-28551241; Email: kyyuen@hkucc.hku.hk
COPYRIGHT 2004 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research
Author:Yuen, K.Y.
Publication:Emerging Infectious Diseases
Geographic Code:1USA
Date:Sep 1, 2004
Words:6622
Previous Article:Laboratory exposures to staphylococcal enterotoxin B.
Next Article:SARS antibody test for serosurveillance.
Topics:


Related Articles
Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality.
Severe acute respiratory syndrome--associated coronavirus in lung tissue.
Patient data, early SARS epidemic, Taiwan.
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.
Laboratory diagnosis of SARS.
SARS and common viral infections.
Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital.
Long-term SARS coronavirus excretion from patient cohort, China.
Neutralizing antibody response and SARS severity.
Pulmonary tuberculosis and SARS, China.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters